Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) in a research note issued on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the company. Canaccord Genuity Group lowered their price target on Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating for the company in a report on Friday, February 24th. Morgan Stanley lowered their target price on Alnylam Pharmaceuticals from $210.00 to $205.00 and set an “equal weight” rating for the company in a research note on Friday, February 24th. Chardan Capital reaffirmed a “buy” rating and issued a $250.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, February 24th. Piper Sandler increased their price objective on shares of Alnylam Pharmaceuticals from $226.00 to $253.00 and gave the stock an “overweight” rating in a research report on Friday, December 16th. Finally, SVB Leerink dropped their price objective on shares of Alnylam Pharmaceuticals from $144.00 to $143.00 and set a “market perform” rating on the stock in a report on Monday, January 23rd. Seven investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $244.26.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $185.45 on Thursday. The company has a market capitalization of $23.02 billion, a price-to-earnings ratio of -20.42 and a beta of 0.49. The firm’s 50 day simple moving average is $213.89 and its 200 day simple moving average is $213.35. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.51 and a quick ratio of 3.34. Alnylam Pharmaceuticals has a fifty-two week low of $117.58 and a fifty-two week high of $242.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last announced its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.13) by $0.45. Alnylam Pharmaceuticals had a negative net margin of 109.04% and a negative return on equity of 1,287.80%. The company had revenue of $335.04 million for the quarter, compared to analysts’ expectations of $312.45 million. During the same period last year, the firm posted ($2.16) earnings per share. The business’s quarterly revenue was up 29.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals will post -6.93 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Indrani Lall Franchini sold 1,675 shares of the firm’s stock in a transaction that occurred on Thursday, February 2nd. The stock was sold at an average price of $226.01, for a total value of $378,566.75. Following the completion of the sale, the executive vice president now directly owns 3,500 shares of the company’s stock, valued at $791,035. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CMO Pushkal Garg sold 18,072 shares of the company’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $200.00, for a total value of $3,614,400.00. Following the transaction, the chief marketing officer now owns 4,345 shares in the company, valued at approximately $869,000. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Indrani Lall Franchini sold 1,675 shares of the firm’s stock in a transaction that occurred on Thursday, February 2nd. The stock was sold at an average price of $226.01, for a total transaction of $378,566.75. Following the sale, the executive vice president now owns 3,500 shares of the company’s stock, valued at $791,035. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently made changes to their positions in ALNY. Nuveen Asset Management LLC increased its position in Alnylam Pharmaceuticals by 5,486.1% during the 3rd quarter. Nuveen Asset Management LLC now owns 16,593,268 shares of the biopharmaceutical company’s stock worth $3,321,309,000 after buying an additional 16,296,223 shares during the period. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock valued at $1,768,291,000 after purchasing an additional 126,373 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Alnylam Pharmaceuticals by 3.0% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,997,082 shares of the biopharmaceutical company’s stock worth $1,020,524,000 after purchasing an additional 202,916 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 0.3% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,202,793 shares of the biopharmaceutical company’s stock worth $761,144,000 after purchasing an additional 10,609 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Alnylam Pharmaceuticals by 2.7% during the second quarter. State Street Corp now owns 2,988,859 shares of the biopharmaceutical company’s stock worth $435,925,000 after purchasing an additional 79,369 shares during the period.

Alnylam Pharmaceuticals Company Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.